Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 5/20 | 0.44 |
| ▸ | ACE | P12821 | 5/20 | 0.44 |
| ▸ | CPA1 | P15085 | 3/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501256 | 0.87 | LNPEP (0.51) | THRBALDH1A1TACR1 | |
| SCHEMBL6501251 | 0.87 | LNPEP (0.51) | THRBALDH1A1TACR1 | |
| SCHEMBL4799500 | 0.82 | LMNA (0.52) | ITGB3ITGA2BLMNAITGB1ITGAV | |
| SCHEMBL6493488 | 0.82 | ITGB3 (0.49) | ITGB3ITGA2BLMNAMMEACE | |
| SCHEMBL4799488 | 0.82 | LMNA (0.52) | ITGB3ITGA2BLMNAITGB1ITGAV | |
| SCHEMBL6493485 | 0.82 | ITGB3 (0.49) | ITGB3ITGA2BLMNAMMEACE | |
| SCHEMBL6504048 | 0.79 | PTPN1 (0.56) | ITGB3ITGA2BLMNAMMEACE | |
| SCHEMBL28820766 | 0.78 | LMNA (0.59) | ITGB3ITGA2BLMNAMMEACE | |
| SCHEMBL8407536 | 0.78 | LMNA (0.59) | ITGB3ITGA2BLMNAMMEACE | |
| SCHEMBL27721631 | 0.77 | ACACB (0.58) | ITGB3ITGA2BLMNAMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | ITGB3 4253/4885ITGA2B 3329/4885LMNA 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.